Tvardi Therapeutics (TVRD)
Develops oral STAT3 inhibitors for cancer and fibrotic diseases.
$1.89
Pre-market+0.02 (+0.96%)
At close$1.87(+7.16%)
Something off on this page? Send us feedback.
Next report
Nov 12, 2026
in 70 days
EPS estimate
−$0.54
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
—May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported—−$3.22−$1.00−$0.59−$0.78−$0.73−$0.69Pending
Estimate—−$0.59−$0.51−$0.83−$0.55−$0.65−$0.70−$0.54
Surprise—−450.4%−96.1%+28.9%−41.8%−12.3%+2.0%—
RevenueReportedEstimate
—May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported—$2.6M—————Pending
Estimate————————
Surprise————————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.54 | — | — |
| Aug 2026 | −$0.70 | −$0.69 | +2.0% |
| May 2026 | −$0.65 | −$0.73 | −12.3% |
| Mar 2026 | −$0.55 | −$0.78 | −41.8% |
| Nov 2025 | −$0.83 | −$0.59 | +28.9% |
The latest year is open to everyone — the 2 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | −$0.54 | — | — | — | — | — | — |
| Aug 13, 2026 | −$0.70 | −$0.69 | +2.0% | — | — | — | −1.1% |
| May 8, 2026 | −$0.65 | −$0.73 | −12.3% | — | — | — | −5.3% |
| Mar 31, 2026 | −$0.55 | −$0.78 | −41.8% | — | — | — | −5.7% |
| Nov 13, 2025 | −$0.83 | −$0.59 | +28.9% | — | — | — | −2.0% |
The latest year is open to everyone — the 2 quarters behind it read with an account. Sign in | |||||||
| Aug 14, 2025 | |||||||
| May 13, 2025 | |||||||